SCB 2020S
Alternative Names: B.1.351 S-Trimer vaccine - Clover Biopharmaceuticals; Endemic coronavirus vaccine - Clover Biopharmaceuticals; Multiple variants SARS-CoV-2 vaccine - Clover Biopharmaceuticals; Multivalent SARS-COV2 vaccine - Clover Biopharmaceuticals; SARS-CoV-2 S-Trimer B.1.351 variant vaccine - Clover Biopharmaceuticals; SCB-2020-SLatest Information Update: 13 Jul 2023
At a glance
- Originator Clover Biopharmaceuticals
- Class COVID-19 vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 23 Apr 2023 Clover Biopharmaceuticals completes phase I trial in COVID-2019 infections (Prevention) in South Africa (IM) (NCT05228314)
- 31 May 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in South Africa (IM) (NCT05228314)
- 05 May 2022 Clover Biopharmaceuticals plans a phase I trial for COVID-2019-infections (Prevention) in 2Q of 2022 (IM) (NCT05228314)